NOT-DA-18-024: Notice of Intent to Publish a Funding Opportunity Announcement for The National Drug Abuse Treatment Clinical Trials Network (UG1) Clinical Trial Optional

Notice of Intent to Publish a Funding Opportunity Announcement for The National Drug Abuse Treatment Clinical Trials Network (UG1) Clinical Trial Optional

Notice Number: NOT-DA-18-024

Key Dates

Release Date: July 11, 2018
Estimated Publication Date of Funding Opportunity Announcement: July 28, 2018
First Estimated Application Due Date: November 01, 2018
Earliest Estimated Award Date: June 01, 2019
Earliest Estimated Start Date: July 01, 2019

Related Announcements
NOT-OD-18-181

Issued by
National Institute on Drug Abuse (NIDA)

Purpose

The National Institute on Drug Abuse (NIDA) intends to publish a Funding Opportunity Announcement (FOA) to solicit applications from clinical investigators to participate in the National Drug Abuse Treatment Clinical Trials Network (CTN). The ongoing opioid epidemic and overdose death crisis present an urgent public health need to quickly expand the CTN to 1) increase the Network’s scientific and clinical research capabilities, and 2) to better cover geographic regions across the United States and regions most impacted by the opioid overdose epidemic. The CTN expansion is part of the NIH Helping to End Addiction Long-Term (HEAL) Initiative.

The purpose of this notice is to allow potential applicants sufficient time to develop meaningful collaborations and projects.

The FOA is expected to be published in August 2018 with an expected application due date in November 2018.

This FOA will utilize the UG1 activity code.

Research Initiative Details

The CTN currently is comprised of 13 research Nodes that serve as research and training centers, with numerous collaborating healthcare organizations or clinical research sites, and two coordinating centers. The CTN program is administered within NIDA through the Center for the Clinical Trials Network (CCTN). The ongoing opioid epidemic and overdose death crisis present a critical public health need to expeditiously augment the CTN research portfolio to enhance treatment options and improve the quality of opioid use disorder (OUD) treatment. NIDA has decided to expand the CTN infrastructure and research portfolio to address and enhance every stage of the cascade of care for OUD. This includes screening and diagnosis of OUD among those affected; linkage to care among those diagnosed with OUD; opioid agonist, partial agonist, or antagonist medication initiation among those entering care; retention for at least six months among those who initiate medication; and relapse prevention or remission among those retained in care. Research on prevention and early intervention for unhealthy opioid use/misuse is also a high priority. Research on prevention and reversal of opioid overdose in the community and emergency departments is another priority. This expansion would enhance the CTN’s ability to use cutting-edge research designs, methods, and data resources. For example, addition of Nodes with expertise in clinical data science and informatics would bolster the CTN’s capacity to conduct pragmatic studies embedded in clinical practice that will inform care. Additional Nodes located in geographic regions severely affected by the opioid epidemic would allow greater reach and impact of research across the country.

As mentioned in NOT-OD-18-181, any for-profit recipient of funds shall be subject to a matching requirement of funds or documented in-kind contributions of not less than 50 percent of the total funds awarded to such entity.

This funding opportunity is being offered as part of the NIH’s Helping to End Addiction Long-term (HEAL) initiative to speed scientific solutions to the national opioid public health crisis. The NIH HEAL Initiative will bolster research across NIH to (1) improve treatment for opioid misuse and addiction and (2) enhance pain management. More information about the HEAL Initiative is available at: https://www.nih.gov/research-training/medical-research-initiatives/heal-initiative.

Funding Information

Estimated Total Funding TBD
Expected Number of Awards TBD
Estimated Award Ceiling TBD
Primary CFDA Numbers TBD

Anticipated Eligible Organizations

Public/State Controlled Institution of Higher Education
Private Institution of Higher Education
Nonprofit with 501(c)(3) IRS Status (Other than Institution of Higher Education)
Nonprofit without 501(c)(3) IRS Status (Other than Institution of Higher Education)
Small Business
For-Profit Organization (Other than Small Business)
State Government
Indian/Native American Tribal Government (Federally Recognized)
County governments
City or township governments
Indian/Native American Tribally Designated Organization (Native American tribal organizations (other than Federally recognized tribal governments)
Indian/Native American Tribal Government (Other than Federally Recognized)
Regional Organization

Applications are not being solicited at this time.

Inquiries

Please direct all inquiries to:

Betty Tai, Ph.D.
NIDA Center for Clinical Trials Network (CCTN)
301-443-2397
[email protected]